Patents Assigned to Children's Medical Center Corporation
  • INHIBITING THE RNA METHYLTRANSFERASE METTL3 OR ITS INTERACTION WITH EIF3H TO SUPPRESS ONCOGENE TRANSLATION AND TUMORIGENESIS
    Publication number: 20230018989
    Abstract: Provided herein are method of treating cancer using agents that inhibit the interaction between Methyltransferase like 3 (METTL3) and Eukaryotic Translation Initiation Factor 3 Subunit H (EIF3h), and optionally agents that inhibit Bromodomain-containing protein 4 (BRD4). The present disclosure demonstrates the topology of individual polyribosomes with single METTL3 foci found in close proximity to 5? cap-binding proteins, revealing a previously unknown direct physical and functional interaction between METTL3 and the eukaryotic translation initiation factor 3 subunit h (eIF3h).
    Type: Application
    Filed: July 2, 2020
    Publication date: January 19, 2023
    Applicant: Children's Medical Center Corporation
    Inventor: Richard I. Gregory
  • AN ANAPLASTIC LYMPHOMA KINASE (ALK) CANCER VACCINE AND METHODS OF USE
    Publication number: 20230020894
    Abstract: Provided herein are isolated anaplastic lymphoma kinase (ALK) peptides that are fragments of the cytoplasmic portion of an ALK protein shared by cancers having an ALK rearrangement and cancers expressing the ALK protein, that bind a human leukocyte antigen (HLA), and elicit an immune response against one or more ALK-positive cancers. Also provided are isolated ALK peptides that are modified with an amphiphilic conjugate to increase T-cell expansion and greatly enhance anti-tumor efficacy. The invention also provides polynucleotides encoding isolated ALK peptides, vaccines comprising an isolated ALK peptide or polynucleotide, immunogenic compositions thereof, and kits for administering the same. Methods of treatment and methods of generating an immune response in a subject by administering the ALK-specific peptide antigens, immunogens, vaccines, or immunogenic compositions thereof are provided.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 19, 2023
    Applicant: Children's Medical Center Corporation
    Inventors: Roberto CHIARLE, Rafael BLASCO-PATINO
  • Devices for analyzing animal behavior
    Patent number: 11553687
    Abstract: A device and method for detecting and recording animal behavior is provided. The device includes an enclosure having first and second chambers, each of the chambers having exterior panels formed of an opaque material, at least one image capture device disposed in each of the first and second chambers, the at least one image capture device arranged to capture behavior data of one or more freely roaming rodents, and a first container insertable into one of the first and second containers and positioned below a respective image capture device, the container having one or more corrals into which one or more rodents are housed during testing, the container being formed of a transparent material. In some embodiments, the first container is formed of a red transparent material, the one or more rodents being unable to see through the red transparent material.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: January 17, 2023
    Assignee: Children's Medical Center Corporation
    Inventors: David P. Roberson, Lee Barrett
  • Valve coaptation measurement devices
    Patent number: 11553893
    Abstract: Methods, systems, and coaptation measurement devices as described herein include an elongate sensor body at the end of a proximal connecting member, and a plurality of sensors in an array across a face of the sensor body, wherein each sensor of the plurality of sensors is configured to detect if a portion of a heart valve is in contact with the sensor.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: January 17, 2023
    Assignee: Children's Medical Center Corporation
    Inventors: David Hoganson, Peter E. Hammer
  • Vaccine nanotechnology
    Patent number: 11547667
    Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: January 10, 2023
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ulrich H. von Andrian, Omid C. Farokhzad, Robert S. Langer, Tobias Junt, Elliott Ashley Moseman, Liangfang Zhang, Pamela Basto, Matteo Iannacone, Frank Alexis
  • Optical bulb for surgical instrument port
    Patent number: 11547276
    Abstract: An optical bulb for a medical device includes first and second bodies. The first body has a substantially hemispherical distal side. The second body extends from the first body and includes a mechanical connection point at or near the proximal side of the second body. An instrument channel extends through the optical bulb from the proximal side of the second body to the distal side of the first body. An imaging channel extends an aperture defined in the proximal side of the second body and terminates between the proximal and substantially hemispherical distal sides of the first body. The distal end of the imaging channel is substantially hemispherical. The first body is configured and arranged to provide a substantially uniform image path within a field of view of a camera disposed in the imaging channel.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: January 10, 2023
    Assignee: The Children's Medical Center Corporation
    Inventors: Anthony Maiorano, Jeffrey C. Cerier, Benjamin D. Masella, David P. Biss, Brian E. MacMillin
  • Compositions and methods for treating lysosomal storage diseases and disorders
    Patent number: 11548936
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a lysosomal disease or disorder involving increasing the level, expression, or activity of a metallothionein polypeptide or polynucleotide in the subject.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: January 10, 2023
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., DANA-FARBER CANCER INSTITUTE, INC., FONDAZIONE TELETHON
    Inventors: Alessandra Biffi, Eleonora Cavalca
  • METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING AN ALLERGY OR ANAPHYLAXIS
    Publication number: 20230003743
    Abstract: Described herein are methods and compositions for treating or preventing an allergy or anaphylaxis. Certain aspects of the invention relate to administering to a subject an agent that inhibits RELM?.
    Type: Application
    Filed: February 23, 2021
    Publication date: January 5, 2023
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Talal Amine Chatila, Elena Crestani, Emmanuel Stephen Victor, Azza Abdel-Gadir, Rima Rachid
  • METHOD FOR TREATING CANCER
    Publication number: 20230003732
    Abstract: Described herein are methods and compositions for treating cancer. Aspects of the invention relate to determining if a biological sample obtained from a subject for GSK3a bodies (puncta), e.g., in response to asparaginase treatment, and administering to a subject having cancer an asparaginase and an agent that inhibits GSK3? to a subject who has been identified as forming GSK3?-positive bodies.
    Type: Application
    Filed: November 3, 2020
    Publication date: January 5, 2023
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Alejandro GUTIERREZ, Laura HINZE
  • CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE
    Publication number: 20230002733
    Abstract: The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.
    Type: Application
    Filed: August 25, 2022
    Publication date: January 5, 2023
    Applicant: The Children's Medical Center Corporation
    Inventor: Paolo Fiorina
  • Therapeutic and diagnostic methods relating to cancer stem cells
    Patent number: 11542328
    Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: January 3, 2023
    Assignees: The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation
    Inventors: Markus H. Frank, Natasha Y. Frank
  • Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
    Patent number: 11542493
    Abstract: Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: January 3, 2023
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Stuart H. Orkin, Daniel E. Bauer, Jian Xu
  • Methods and agents that enhance myogenic progenitor cell engraftment
    Patent number: 11534418
    Abstract: Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: December 27, 2022
    Assignees: President and Fellows of Harvard College, The Children's Medical Center Corporation
    Inventors: Sahar Tavakoli, Amy J. Wagers, Leonard Zon
  • Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
    Patent number: 11530253
    Abstract: The present disclosure provides genetically modified antibody-producing cells comprising edited chromosomal sequences associated with immunoglobulin heavy chain constant region, the IgH locus. In particular, these cells are generated using a CRISPR/Cas 9-mediated editing process. The disclosure also provides specific guide RNA (gRNA) guide sequences that target the chromosomal sequence of immunoglobulin heavy chain constant region in the Switch regions.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: December 20, 2022
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Roberto Chiarle, Taek-Chin Cheong
  • COMPOSITIONS AND METHODS FOR GENE REPLACEMENT
    Publication number: 20220395583
    Abstract: The present invention features a dual vector system for disrupting and replacing a target gene comprising a mutation (e.g., dominant, recessive mutation). Embodiments of the invention may also provide compositions comprising the dual vector system, and methods of using the dual vector system, including but not limited to methods of modifying the genome of a cell, methods of genomic editing, and methods of treating cells or a subject suffering from a genetic disease comprising a mutation.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 15, 2022
    Applicant: Children's Medical Center Corporation
    Inventor: Jeffrey R. HOLT
  • Immune cells derived from induced pluripotent stem cell
    Patent number: 11525119
    Abstract: Embodiments disclosed here are production methods and compositions of engineered immune cells, such as B or T lymphocytes, from limited lineage myeloid progenitor cells, or from pluripotent stem cells, or from multilineage hematopoietic progenitor cells comprising the addition of various cell differentiation transcription factors and inhibiting epigenetic histone methylations in said cells.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: December 13, 2022
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Linda Thuy Vo, George Q. Daley
  • METHODS AND COMPOSITIONS FOR CHARACTERIZING INFLAMMATORY BOWEL DISEASE
    Publication number: 20220390464
    Abstract: The invention features compositions and methods for characterizing inflammatory bowel disease and inflammatory bowel disease subtypes, such as well Crohn's disease and ulcerative colitis. In one aspect, the invention provides a panel for characterizing inflammatory bowel disease, the panel including two or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25) capture molecules each bound to a substrate, wherein each capture molecule specifically binds a marker polypeptide selected from one or more of the following: CD3, CD4, CDS, CD24, CD25, CD27, CD38, CD44, CD45RA, CD45RO, CD127, CD161, CTLA-4, CXCR3, CCR4, CCR6, CCR7, FOXP3, HLA-DR, IFN?, IL-10, IL-17A, IL-21, IL-22, CD11c, IL23p19, CD66b, CD163, CD44, ckit, CD16, NKp46, AHR, and TNF?, or a polynucleotide encoding said marker polypeptide.
    Type: Application
    Filed: July 27, 2020
    Publication date: December 8, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: Scott B. SNAPPER, Vanessa MITSIALIS, Liza KONNIKOVA
  • Methods and compositions for regulating gene expression
    Patent number: 11517630
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: December 6, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Richard Mulligan, George J. Murphy
  • NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF
    Publication number: 20220378895
    Abstract: The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.
    Type: Application
    Filed: January 7, 2022
    Publication date: December 1, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: Richard Malley, Yingjie Lu, Kristin L. Moffitt
  • COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
    Publication number: 20220378942
    Abstract: The present disclosure features methods and compositions for treating Alzheimer's disease. The disclosed methods comprise administering to a subject having or suspected of having Alzheimer's a hematopoietic stem progenitor cell expressing at least one neuroprotective agent, such as ApoE2, Trem2, and/or a metallothionein.
    Type: Application
    Filed: October 1, 2020
    Publication date: December 1, 2022
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Alessandra BIFFI, Marco PEVIANI